Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Neos Therapeutics, Inc. (NEOS) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/29/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
03/26/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/26/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/26/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/26/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/22/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...
Docs: "Fifth Amended and Restated Certificate of Incorporation of Neos Therapeutics, Inc",
"Second Amended and Restated Bylaws of Neos Therapeutics, Inc",
"Consent, Waiver and Sixth Amendment to Facility Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, Deerfield Private Design Fund III L.P., Deerfield Partners, L.P. and Deerfield Mgmt, L.P.",
"Consent, Waiver and Amendment No. 1 to Loan and Security Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, and Encina Business Credit, LLC",
"Aytu BioScience Announces Close of Merger with Neos Therapeutics"
03/22/2021 425 Form 425 - Prospectuses and communications, business combinations:
03/19/2021 4 Limongelli John M (SVP & General Counsel) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 83,015 shares @ $0
Disposed/sold 150,000 options to buy @ $3.14, valued at $471k
Disposed/sold 115,000 options to buy @ $1.49, valued at $171.4k
03/19/2021 4 Robinson James A. Jr. (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 23,453 shares @ $0
Disposed/sold 12,500 options to buy @ $2.03, valued at $25.4k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 McLaughlin Gerald W. (CEO) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 270,171 shares @ $0
Disposed/sold 600,000 options to buy @ $6.2, valued at $3.7M
Disposed/sold 392,688 options to buy @ $2.31, valued at $907.1k
Disposed/sold 395,000 options to buy @ $1.49, valued at $588.6k
Disposed/sold 100,000 options to buy @ $5.55, valued at $555k
Disposed/sold 65,447 options to buy @ $2.31, valued at $151.2k
03/19/2021 4 Hecht Beth (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 23,453 shares @ $0
Disposed/sold 12,500 options to buy @ $19.82, valued at $247.8k
Disposed/sold 14,777 options to buy @ $9.63, valued at $142.3k
Disposed/sold 18,322 options to buy @ $7.65, valued at $140.2k
Disposed/sold 22,756 options to buy @ $6.05, valued at $137.7k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 Schmid John P. (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 23,453 shares @ $0
Disposed/sold 12,500 options to buy @ $10.73, valued at $134.1k
Disposed/sold 14,777 options to buy @ $9.63, valued at $142.3k
Disposed/sold 18,322 options to buy @ $7.65, valued at $140.2k
Disposed/sold 22,756 options to buy @ $6.05, valued at $137.7k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 Fong Bryant (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 24,953 shares @ $0
Disposed/sold 12,500 options to buy @ $15, valued at $187.5k
Disposed/sold 14,777 options to buy @ $9.63, valued at $142.3k
Disposed/sold 18,322 options to buy @ $7.65, valued at $140.2k
Disposed/sold 22,756 options to buy @ $6.05, valued at $137.7k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 Szyper Linda M (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 23,453 shares @ $0
Disposed/sold 12,500 options to buy @ $8.4, valued at $105k
Disposed/sold 22,756 options to buy @ $6.05, valued at $137.7k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 ROBITAILLE GREGORY J (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 79,130 shares @ $0
Disposed/sold 10,416 options to buy @ $9.32, valued at $97.1k
Disposed/sold 12,500 options to buy @ $15, valued at $187.5k
Disposed/sold 14,777 options to buy @ $9.63, valued at $142.3k
Disposed/sold 18,322 options to buy @ $7.65, valued at $140.2k
Disposed/sold 22,756 options to buy @ $6.05, valued at $137.7k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 HELLER ALAN L (Director) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 446,819 shares @ $0
Disposed/sold 12,500 options to buy @ $15, valued at $187.5k
Disposed/sold 14,777 options to buy @ $9.63, valued at $142.3k
Disposed/sold 18,322 options to buy @ $7.65, valued at $140.2k
Disposed/sold 22,756 options to buy @ $6.05, valued at $137.7k
Disposed/sold 46,907 options to buy @ $1.44, valued at $67.5k
03/19/2021 4 Eisenstadt Richard I (CFO) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Disposed/sold 126,245 shares @ $0
Disposed/sold 86,167 options to buy @ $2.91, valued at $250.7k
Disposed/sold 12,500 options to buy @ $9.32, valued at $116.5k
Disposed/sold 60,230 options to buy @ $25.5, valued at $1.5M
Disposed/sold 50,000 options to buy @ $10.74, valued at $537k
Disposed/sold 45,000 options to buy @ $7, valued at $315k
Disposed/sold 56,250 options to buy @ $8.3, valued at $466.9k
Disposed/sold 230,276 options to buy @ $2.31, valued at $531.9k
Disposed/sold 115,000 options to buy @ $1.49, valued at $171.4k
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/19/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/19/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/19/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/19/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/16/2021 4 McLaughlin Gerald W. (CEO) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Paid exercise price by delivering 44,329 shares @ $0.844, valued at $37.4k
03/16/2021 4 Limongelli John M (SVP & General Counsel) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Paid exercise price by delivering 16,985 shares @ $0.844, valued at $14.3k
03/16/2021 4 Eisenstadt Richard I (CFO) has filed a Form 4 on Neos Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,390 shares @ $0.883, valued at $1.2k
Paid exercise price by delivering 14,825 shares @ $0.844, valued at $12.5k
03/12/2021 425 Form 425 - Prospectuses and communications, business combinations:
03/12/2021 GN Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy